ERBB2 and breast carcinoma: The ERBB2, TP53, EGFR, NF1, and SETD2 mutations were identified in HER2+ breast cancer as contributing to trastuzumab resistance, whereas in HER2- breast cancer patients with resistance to chemotherapy, genetic variations in the TP53, PIK3CA, and DNA damage repair genes were shown.